Related Experiment Videos
Hormone replacement therapy and the cardiovascular system. Nonlipid effects
J C Stevenson1, D Crook, I F Godsland
1Wynn Institute for Metabolic Research, London, England.
Insights
Hormone replacement therapy (HRT) significantly reduces coronary heart disease (CHD) risk in postmenopausal women. Beyond lipid changes, HRT improves insulin sensitivity, body fat distribution, and arterial function, offering cardiovascular protection.
Area of Science:
- Cardiovascular endocrinology
- Menopause research
- Metabolic syndrome
Background:
- Coronary heart disease (CHD) is a leading cause of mortality in women, with risk escalating post-menopause.
- Loss of ovarian function significantly impacts cardiovascular health and metabolic risk factors.
Purpose of the Study:
- To elucidate the multifaceted cardiovascular protective effects of hormone replacement therapy (HRT) in postmenopausal women.
- To investigate non-lipid mediated benefits of HRT on cardiovascular risk factors.
Main Methods:
- Review of existing literature on HRT, gonadal steroid hormones, and cardiovascular disease.
- Analysis of HRT's impact on metabolic parameters, including glucose and insulin metabolism.
- Assessment of HRT's direct effects on arterial function and thrombosis.
Main Results:
- HRT reduces CHD incidence by 50% in postmenopausal women.
- Estradiol improves insulin sensitivity and glucose metabolism, counteracting menopausal effects.
- HRT favorably alters fat distribution, coagulation/fibrinolysis balance, and has direct arterial benefits.
Conclusions:
- HRT offers significant cardiovascular protection beyond lipid modification.
- Non-lipid effects of HRT, including metabolic and direct arterial actions, are crucial for reducing CHD risk.
- Estradiol plays a key role in HRT's cardioprotective mechanisms.
Abstract:
Coronary heart disease (CHD) is the leading cause of death in women, and the risk of this disease rises markedly after loss of ovarian function. Hormone replacement therapy (HRT) can reduce the incidence of CHD in postmenopausal women by 50%. HRT causes changes in lipids and lipoproteins, but it is now clear that many other effects of gonadal steroid hormones have important influences on the cardiovascular system. These nonlipid effects include a variety of changes in other metabolic risk factors for CHD, as well as direct arterial effects. Insulin resistance and hyperinsulinaemia may be pivotal disturbances in the pathogenesis of CHD. Estradiol reverses the effects of menopause on glucose and insulin metabolism, resulting in an increase in pancreatic insulin secretion and a decrease in insulin resistance, although other types of estrogen may not do this. Androgenic progestogens may oppose this potentially beneficial effect on insulin resistance. Central obesity is linked with many CHD risk factors, and HRT reverses the increased fat distribution that results from loss of ovarian function at the menopause. HRT may also improve the balance between coagulation and fibrinolysis, resulting in a reduction in arterial thrombosis. Finally, estradiol acts directly on the arterial wall, modifying both endothelium-dependent and calcium-dependent processes. These actions result in improved blood flow and reduced blood pressure and, importantly, have the potential to reduce myocardial ischaemia.